Efficacy and safety in SGLT2 inhibitor for diabetes complicated by non-alcoholic fatty liver disease.

Efficacy and safety in SGLT2 inhibitor for diabetes complicated by non-alcoholic fatty liver disease. - SGLT2 inhibitor for diabetes complicated by NAFLD.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018166

Enrollment

Registered

2015-07-02

Start date

2015-10-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes complicated by non-alcoholic fatty liver disease

Interventions

SGLT2 inhibitor is administered orally for 24 weeks or more.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes with liver dysfunction, and/or fatty liver diagnosed by abdominal ultrasonography.

Exclusion criteria

Exclusion criteria: Contraindication for SGLT2 inhibitor. Ineligible patients by judgement of family doctor.

Design outcomes

Primary

Measure	Time frame
Histologial changes of liver and safety of treament are evaluated at two points of the baseline and 24 weeks after the start of treatment.	—

Secondary

Measure	Time frame
Fasting plasma glucose, hemoglobin A1c, aspartate aminotransferase, alanine aminotransferase, and body composition are evaluated at two points of the baseline and 24 weeks after the start of treatment.	—

Countries

Japan

Contacts

Public ContactNorio Akuta

Toranomon Hospital Hepatology

norioakuta@toranomon.gr.jp044-877-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026